procedure questions and safety

By the Regenerative Evidence Guide Team What Does "Investigational New Drug (IND)" Status Actually Mean? An Investigational New Drug (IND) application is a Food and Drug Administration (FDA) filing …

Continue Reading about Investigational New Drug (IND) Language: What It Does—and Does Not—Signal →

By the Regenerative Evidence Guide Team What an Institutional Review Board does, in plain terms An Institutional Review Board (IRB) is a federally required committee that reviews human-subjects …

Continue Reading about What an Institutional Review Board Does in Clinical Research →

By the Regenerative Evidence Guide Team An adverse event report is a description of a health problem someone experienced after using a medical product, filed with a regulator like the FDA. A single …

Continue Reading about Adverse Event Reports and Safety Evidence: What Each Can—and Cannot—Show →

By the Regenerative Evidence Guide Team Research consent is the process of learning what a clinical study involves — its purpose, risks, benefits, and alternatives — before you agree to take part. If …

Continue Reading about Research Consent for a Clinical Study: What to Ask First →

By the Regenerative Evidence Guide Team Are Exosome Products FDA-Approved? The Short Answer No exosome product is currently approved by the U.S. Food and Drug Administration (FDA) for sale in the …

Continue Reading about Exosome Products: Regulatory Questions and Safety Boundaries →

By the Regenerative Evidence Guide Team By Regenerative Evidence Guide Editorial Team · Updated September 8, 2026 Ask about FDA approval status, clinical trial oversight, product source, and known …

Continue Reading about Questions to Ask Before a Regenerative-Medicine Procedure Conversation →